港股異動丨冠華國際控股(00539.HK)大跌近25% 折讓30%1供2
格隆匯5月12日丨冠華國際控股(00539.HK)往常交易平淡,今放量大跌24.88%,跌幅居港股市場首位,報0.151港元盤中創下2009年4月以來新低,暫成交491萬港元,最新總市值1.2億港元。冠華國際控股昨日公佈,董事會建議按“1供2”基準供股,以每股供股股份0.140港元發行15.54億股,較上交易日(11日)收報折讓30.35%,籌集所得款項總額約2.175億港元。值得一提的是,在去年12月公司擬“1供2”基準折讓22.86%供股,淨籌4.125億港元。然而所得款項均有用於償還銀行貸款。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.